RecruitingNot ApplicableNCT05977751

Prospective Multi-Center Trial for FemBloc Permanent Birth Control

FINALE: Prospective Multi-Center Trial for FemBloc INtratubal Occlusion for TranscervicAL PErmanent Birth Control


Sponsor

Femasys Inc.

Enrollment

573 participants

Start Date

Oct 31, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Prospective, multi-center, international, unblinded, single-arm trial of subjects undergoing FemBloc followed by ultrasound confirmation test.


Eligibility

Sex: FEMALEMin Age: 21 YearsMax Age: 50 Years

Inclusion Criteria3

  • Female, 21 - 50 years of age desiring permanent birth control.
  • Sexually active with male partner.
  • Regular menstrual cycle for last 3 months or on hormonal contraceptives.

Exclusion Criteria6

  • Uncertainty about the desire to end fertility.
  • Known or suspected pregnancy.
  • Prior tubal surgery, including sterilization attempt.
  • Presence, suspicion, or previous history of gynecologic malignancy.
  • Scheduled to undergo concomitant intrauterine procedures (i.e. endometrial ablation) at the time of either FemBloc Treatment or prior to final confirmation test.
  • Abnormal uterine bleeding requiring evaluation or treatment.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEFemBloc

Treatment for women who desire non-surgical permanent birth control by occlusion of the fallopian tubes.


Locations(8)

New Horizons Clinical Trials

Chandler, Arizona, United States

Stanford University

Palo Alto, California, United States

University of California Davis

Sacramento, California, United States

Midtown OB GYN North

Columbus, Georgia, United States

Rosemark WomenCare Specialists

Idaho Falls, Idaho, United States

Maimonides Medical Center

Brooklyn, New York, United States

Seven Hills Women's Health Centers

Cincinnati, Ohio, United States

University of Utah

Salt Lake City, Utah, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05977751


Related Trials